Holen Sie sich die Stockscreener-App
8.36
4.50%
0.36
Handel nachbörslich:
8.15
-0.21
-2.51%
Schlusskurs vom Vortag:
$8.00
Offen:
$8.4
24-Stunden-Volumen:
5,204
Relative Volume:
0.64
Marktkapitalisierung:
$67.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+3.08%
1M Leistung:
+24.04%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$7.698
$8.40
1-Wochen-Bereich:
$7.62
$8.40
52-Wochen-Spanne:
$6.50
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
Firmenname
Scienture Holdings Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie SCNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SCNX | 8.36 | 67.16M | 0 | 0 | 0 | 0.00 |
| WBA | 8.66 | 7.48B | 147.66B | -8.64B | -363.00M | -3.57 |
| HITI | 2.57 | 208.95M | 376.07M | -22.41M | 18.73M | -0.7065 |
| PETS | 4.47 | 94.95M | 270.52M | -6.08M | 17.42M | -0.1609 |
| CJJD | 2.01 | 14.37M | 148.81M | -21.14M | 0 | -0.9969 |
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Walgreens Boots Alliance (WBA) Stock Surges Amid Market Activity - GuruFocus.com
Scienture Holdings: Q3 Earnings Snapshot - CTPost
White Mountains: Q3 Earnings Snapshot - AOL
Scienture completes preferred stock conversion By Investing.com - Investing.com Australia
Scienture completes preferred stock conversion - Investing.com India
Scienture : Material Event Form 8 K - Marketscreener.com
Scienture Holdings Shares Insight with Investor Presentation - TipRanks
Gajan A. Mahendiran and Amudha Mahendiran acquired Westminster Pharmaceutical LLC from Trxade Group, Inc. for $1.6 million. - Marketscreener.com
Top Premarket Gainers - Marketscreener.com
Scienture Holdings Unveils New Identity Post-Merger - TipRanks
TRxADE Health changes its name to Scienture Holdings - AlphaStreet
Bats Reveal Superior Adaptation to Endure Heart Stress: National Heart Centre Singapore Partners Paratus Sciences Singapore to Accelerate Heart Failure Care - ForexTV.com
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner - ForexTV.com
TRxADE Health rebrands as Scienture Holdings with new ticker SCNX - Investing.com
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX” - Morningstar
SCNXScienture Holdings, Inc. Latest Stock News & Market Updates - StockTitan
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. - ForexTV.com
Trxade Health announces name change to Scienture Holdings - TipRanks
Guardian Pharmacy seeks to raise up to $108 mil in US IPO - AlphaStreet
Everything you need to know about Zenas BioPharma’s IPO - AlphaStreet
Trxade Group’s Strategic Merger and Rebranding as Scienture Holdings - TipRanks
TRxADE HEALTH completes all-stock merger deal with Scienture - World Pharmaceutical Frontiers
Trxade Health closes business combination with Scienture in $103Mln deal - AlphaStreet
Envoy Medical is well-positioned to gain market share in hearing implant space: CEO - AlphaStreet
AgEagle’s latest focus is on tailoring products for defense, public safety industries: CEO - AlphaStreet
Everything you need to know about OS Therapies’ upcoming IPO - AlphaStreet
MEDS Earnings: Highlights of Trxade Health’s Q1 2024 financial results - AlphaStreet
TRxADE Health, Inc. Files its Q1 10-Q; Reporting Positive Net Income Due to Asset Sale - StockTitan
Alumis looks to raise $300 million in IPO. Here’s what you need to know - AlphaStreet
Tempus AI gears up for IPO. Here’s everything you need to know - AlphaStreet
Trxade Health Inc. (NASDAQ: MEDS) Q1 2024 Research Summary - AlphaStreet
Femasys is committed to providing women with revolutionary healthcare products: CEO - AlphaStreet
Trxade Health, Inc. Announces Special Cash Dividend, Payable on or About March 22, 2024 - Marketscreener.com
Trxade Health Inc. (NASDAQ: MEDS) Q4 2023 Research Summary - AlphaStreet
MEDS Earnings: A snapshot of Trxade Health’s Q3 2023 financial results - AlphaStreet
TRxADE: Q3 Earnings Snapshot - Marketscreener.com
Nordic Group makes another acquisition to diversify earnings base - Yahoo Finance
Trxade Health Inc. (NASDAQ: MEDS) Q3 2023 Research Summary - AlphaStreet
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor - AlphaStreet
symbol__ Stock Quote Price and Forecast - CNN
Continued focus on core B2B segment drives new business: Trxade CEO Suren Ajjarapu - AlphaStreet
TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel - AlphaStreet
Earnings: Trxade Health (MEDS) reports 16% rise in FY22 revenue; loss narrows - AlphaStreet
TRxADE HEALTH, Inc. Announces Janet Huffman, the Chief Financial Officer Terminate Her Offer Letter and Transitioned from Chief Financial Officer to Acting Chief Financial Officer - Marketscreener.com
Current initiatives should enable Flux Power to reach profitability: CEO Ron Dutt - AlphaStreet
Trxade Health Inc. (NASDAQ: MEDS) Q4 2022 Research Summary - AlphaStreet
Trxade (MEDS) is increasing the breadth of product offerings: CEO Suren Ajjarapu - AlphaStreet
Trxade CEO Suren Ajjarapu: Will see the impact of GPO program by Q3 next year - AlphaStreet
Trxade Health beats on Q3 revenue estimate - AlphaStreet
IPO News: Here’s what to know when Sera Prognostics goes public this week - AlphaStreet
MEDSTRxADE HEALTH, Inc. Latest Stock News & Market Updates - StockTitan
Finanzdaten der Scienture Holdings Inc-Aktie (SCNX)
Es liegen keine Finanzdaten für Scienture Holdings Inc (SCNX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
4.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):